New drug combo targets Hard-to-Treat cancers

NCT ID NCT04497116

Completed Disease control Sponsor: Repare Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkage. The trial is now complete, and results will help guide future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RP-3500 (camonsertib), talazoparib, gemcitabine
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have certain genetic changes.
What could go wrong: This is an early-phase trial focused on safety and dosing, not yet proven to work. The drugs may cause side effects, and the benefit for patients is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

#1001, The University of Texas M.D. Anderson Cancer Center

Houston, Texas, 77030, United States
#1002, Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
#1003, Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
#1004, Memorial Sloan Kettering Cancer Institute

New York, New York, 10065, United States
#1005, Duke Cancer Institute

Durham, North Carolina, 27710, United States
#1006, Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
#1007, Rhode Island Hospital

Providence, Rhode Island, 02903, United States
#1014, Northwestern University

Chicago, Illinois, 60611, United States
#2001, Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
#3001, The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
#3002, Freeman Hospital Newcastle

Newcastle upon Tyne, NE7 7DN, United Kingdom
#3003, Sarah Cannon Research Institute

London, W1G 6AD, United Kingdom
#4001, Copenhagen University Hospital Rigshospitalet - Blegdamsvej

Copenhagen, DK, 2100 Ø, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.